The annual surge of respiratory viruses — flu, COVID-19 and RSV — is in full swing, straining health systems and sparking ...
The risk of respiratory syncytial virus, or RSV, is on the rise, along with that of other illnesses including the flu, stomach flu and COVID-19.
Respiratory syncytial virus, or RSV, is a common respiratory virus that infects the nose, throat, and lungs. According to the CDC, RSV symptoms make it difficult to distinguish it from the common ...
for increased sickness. The winter and holiday season is typically when more people get sick, particularly with respiratory viruses such as the flu, RSV and COVID-19. While most of us have heard ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Though there are now respiratory syncytial virus (RSV) vaccines approved by the FDA and recommended by the CDC for ...
Flu cases are beginning to rise after a slow start to the season, with respiratory illnesses increasing nationwide in the ...
In a new study, the RSV drug nirsevimab was 93% effective at preventing young children from being hospitalized for the respiratory infection. A new RSV drug designed to protect young children was ...
Even if you lead an active, healthy lifestyle, viruses like RSV (respiratory syncytial virus) can affect anyone. RSV may just lead to cold-like symptoms, but if you’re 60 and older with certain ...
In trials, GSK’s vaccine significantly reduced the risk of developing RSV-associated lower respiratory tract disease by 83% and the risk of severe disease by 94%. As it stands, GSK looks like it ...